We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

BIOHIT Healthcare OY

Offers technologies and services for diagnosing and preventing gastrointestinal diseases and associated risks read more Featured Products: More products

Download Mobile App




Biohit's GastroPanel Blood Test Accurately Diagnoses Hp Infection and AG Before Endoscopy

By LabMedica International staff writers
Posted on 09 May 2022

Helicobacter pylori (Hp) infection, atrophic gastritis (AG) and high acid output are important risk factors for gastric and esophageal cancers. More...

Now, the latest study to evaluate the diagnostic accuracy of a unique blood test for the diagnosis of both AG and Hp infection in patients referred for gastroscopy from primary care with different indications has confirmed its high accuracy.

Biohit Oyj’s (Helsinki, Finland) new generation GastroPanel test is designed for the first-line diagnosis of Hp infection and AG in patients with upper abdominal symptoms, such as dyspepsia and gastro-oesophageal reflux disease (GORD), before endoscopy. GastroPanel is also the only test on the market capable of monitoring the regulatory mechanism of acid output in the stomach. The new generation (unified) GastroPanel test works on the same principle as the original GastroPanel ELISA test and is designed to harmonize the ELISA processing conditions of four biomarkers.

The highly informative GastroPanel assay is a cost-effective solution for population-based screening for the risk of gastric cancer in asymptomatic and symptomatic individuals, and its efficacy has already been confirmed by several studies in both high- and low-risk countries. Along with the previously published clinical validation studies, the latest biopsy-confirmed study was designed to verify the diagnostic capabilities of the new generation GastroPanel test compared to the current gold standard (gastroscopy and biopsy analysis), and to demonstrate its performance was comparable to the original GastroPanel test. The positive results from the study pave the way for BIOHIT’s new GastroPanel Quick Test (point of care test) which will be launched in Q1 2022.

“A total of 522 patients referred for gastroscopy at the Gastro Centre, OUH, were consented and enrolled for this particular study,” said Dr. Olli-Pekka Koivurova, Principal Investigator of the study. "Blood was sampled for all patients using the GastroPanel test, along with performing quality-controlled gastroscopies with mucosal biopsies. The results confirmed that the new generation GastroPanel is a highly accurate test for the non-invasive diagnosis of AG and Hp infection in patients referred for diagnostic gastroscopies.”

Related Links:
Biohit Oyj


New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.